This model included risk factors such as patient age, cancer type, prior chemotherapy, laboratory measurements for abnormal hepatic and renal functions, low white blood cell (WBC) count, chemotherapy agents and planned relative dose intensity (RDI) ≥85%, concurrent immunosuppressive therapy, and receipt of G‐CSF prophylaxis as predictors for severe neutropenia or FN.7 This model has been validated in a study using electronic medical records (EMRs) from an external retrospective cohort of adult patients with cancer.8 Here, CSF3 is linked to cancer.